You can take Metozolv ODT anywhere, without liquid
Metozolv ODT changes the way you take metoclopramide. It’s the first available orally disintegrating tablet that treats diabetic gastroparesis and refractory GERD.1-3 Because it rapidly* melts on the tongue, you can conveniently take it anywhere, without liquid.
Metozolv ODT is available in 5-mg and 10-mg orally disintegrating tablets.1
It can be taken up to 4 times a day, at least 30 minutes before each meal and at bedtime.1 Dosage can depend on symptoms and other factors, so take Metozolv ODT only as directed by your healthcare professional.
Convenience on the go
Metozolv ODT makes it convenient to take your medicine as prescribed. Simply remove the tablet from its packaging and place it on your tongue. It rapidly* melts on the tongue and does not need to be taken with liquid. Thanks to this convenient feature, you can take Metozolv ODT in situations where you may not be able to take a regular metoclopramide tablet.
Talk to your healthcare professional about Metozolv ODT
If you are currently taking traditional metoclopramide tablets and would like to take an orally disintegrating tablet to treat diabetic gastroparesis symptoms or refractory GERD, talk to your healthcare professional about Metozolv ODT.
Is Metozolv ODT right for you?
Discover valuable tools and resources about diabetic gastroparesis, refractory GERD, and Metozolv ODT
*Metozolv ODT disintegrates on the tongue in a median of 53.5 seconds (mean ± standard deviation, 76.8 ± 110.6 seconds).1
References: 1. METOZOLV ODT [package insert]. Morrisville, NC: Salix Pharmaceuticals, Inc; 2009.
2. Overview. US Food and Drug Administration. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=REGLAN. Accessed May 6, 2009.
3. Overview. US Food and Drug Administration. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=METOCLOPRAMIDE%20HYDROCHLORIDE. Accessed May 6, 2009.
IMPORTANT SAFETY INFORMATION
Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive
dyskinesia increases with the duration of treatment and the total cumulative dose.
Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive
dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.
Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh
the risk of developing tardive dyskinesia.
METOZOLV™ ODT (metoclopramide HCl) is indicated as short-term therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD)
who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric
stasis) in adults. Therapy should not exceed 12 weeks in duration. METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage,
or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal
reactions. METOZOLV ODT should be used with caution in patients showing acute dystonic reactions, drug-induced Parkinsonism, or other extrapyramidal symptoms;
neuroleptic malignant syndrome; with a prior history of depression; hypertension; congestive heart failure and ventricular arrhythmia. Patients may experience
withdrawal symptoms after stopping the use of METOZOLV ODT.
In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.
Please see accompanying full Prescribing Information
for Metozolv ODT, including BOXED WARNING.